Previous 10 | Next 10 |
Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company Q2 Consumer Health division revenue reaches an all-time high of $7.9 million Q2 Rx division revenue up 24% sequentially Ended the quarter wit...
– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu...
Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / February 4, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that t...
Are These On Your List Of Penny Stocks To Buy Or Avoid? This year is off to a roaring start, and penny stocks are partly to blame. It’s the end of January, and several factors are impacting the overall stock market. To find the best penny stocks to buy, we have to consider al...
Merger activity decreased last week with six new deals announced. Acacia Communications and Cisco Systems announced an amendment to their merger agreement. Google completes the acquisition of Fitbit. For further details see: Merger Arbitrage Mondays - Fitbit Closes And A...
Merger activity decreased last week with one new deal announced. The acquisition of Red Lion Hotels (RLH) by Sonesta International Hotels. Perella Weinberg Partners and FinTech Acquisition Corp. IV enter into a definitive business combination agreement. For further details s...
Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant upside potential and numerous exciting catalysts to be announced that could drive sig...
Aytu BioScience (AYTU) is up 4.3% in premarket trading as the company announces the completion of the safety study for the use of ultraviolet A light as a COVID-19 treatment.The single-center, U.S.-based study evaluated the safety and proof of principle of Aytu’s He...
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on ...
ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underw...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...